Breaking News

Gallus Enters ADC Mfg. Agreement with Progenics

August 21, 2014

To produce prostate cancer drug at its commercial facility in St. Louis

Gallus BioPharmaceuticals, LLC has been selected by Progenics Pharmaceuticals, Inc. to manufacture the anti-prostate specific membrane antigen (PSMA) monoclonal antibody used in its PSMA ADC product candidate. Gallus will produce the antibody at its commercial manufacturing facility in St. Louis, MO.
 
PSMA ADC is a fully human monoclonal antibody-drug conjugate designed to deliver chemotherapeutic drug to prostate cancer cells by targeting PSMA, a protein that is a biomarker of prostate cancer. The PSMA antibody is designed enter the cancer cell and release active anti-cancer drug.
 
“Our extensive commercial manufacturing experience and proven quality systems make Gallus an ideal partner to support Progenics in the manufacture of their anti-PSMA antibody," said Mark R. Bamforth, president and chief executive officer of Gallus. "We look forward to working with Progenics as they advance this treatment for patients with prostate cancer."
 
"Gallus has impressed us with their ability to meet our high standards, combined with the experience and expertise necessary to manufacture our anti-PSMA antibody,” said Nitya Ray, Ph.D., senior vice president of manufacturing at Progenics. “We look forward to a productive partnership with Gallus as we develop this product for patients in need of this therapy."

Related Packaging:

Related Contract Manufacturing:

Related Compliance:

blog comments powered by Disqus
  • API Sourcing Trends

    Kristin Brooks, Contract Pharma||April 11, 2016
    Drug product complexities, quality and regulatory hurdles drive market shift

  • U.S. Pharma Market Trends

    Kristin Brooks, Contract Pharma||April 8, 2016
    CPhI Report sees return of generic and API manufacturing to U.S. market

  • Flexible Manufacturing Strategies

    Kristin Brooks, Contract Pharma||April 4, 2016
    Michael Lehmann of Patheon discusses solutions for pharmaceutical forecasting errors

  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.